Motapizone  (Synonyms: NAT 05-239)

Motapizone (NAT 05-239) is a selective PDE3 inhibitor. Motapizone moderately inhibits cytokine release in lipopolysaccharide (LPS)-induced alveolar macrophages. Motapizone also inhibits human platelet aggregation by increasing intracellular cAMP^[1][2].

Motapizone (10 μM; 15 min before oxidants) results 20% inhibition rate for cytokine release in lipopolysaccharide (LPS)-induced alveolar macrophages with oxidative stress conditions, but the inhibitory effect is not affected by oxidative stress^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

260.31

C₁₂H₁₂N₄OS

90697-57-7

Solid

Light yellow to yellow

CC(C1)C(C2=CC(N3C=CN=C3)=CS2)=NNC1=O

Room temperature in continental US; may vary elsewhere.

* Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

• [1]. Milara J, et al. Oxidative stress-induced glucocorticoid resistance is prevented by dual PDE3/PDE4 inhibition in human alveolar macrophages. Clin Exp Allergy. 2011 Apr;41(4):535-46.  [Content Brief]

  [2]. Borbe HO, et al. Inhibition of human platelet aggregation by motapizone via an increase in intracellular cAMP. Agents Actions Suppl. 1986;20:249-57.  [Content Brief]